Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
About Amgen Inc.
Amgen Inc. (NASDAQ: AMGN) is a leading multinational biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980, Amgen is one of the world's largest independent biotechnology firms, pioneering the development of innovative medicines that leverage human genetic data to address some of the most challenging diseases. With a mission to serve patients, Amgen focuses on using cutting-edge science and technology to discover, develop, manufacture, and deliver transformative therapies.
Core Therapeutic Areas
Amgen's portfolio spans several therapeutic areas, including:
- Oncology: Amgen develops targeted therapies for cancers, such as LUMAKRAS® for KRAS G12C-mutated non-small cell lung cancer and BLINCYTO® for B-cell acute lymphoblastic leukemia (B-ALL).
- Inflammation: Products like TEZSPIRE® (tezepelumab) address severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
- Cardiovascular Diseases: Repatha® is a leading treatment for lowering LDL cholesterol and reducing cardiovascular risks.
- Rare Diseases: Amgen's acquisition of Horizon Therapeutics has expanded its rare disease portfolio, including treatments like TEPEZZA® for thyroid eye disease.
- Obesity and Metabolic Health: Investigational therapies like MariTide (AMG 133) are being developed to address obesity and Type 2 diabetes.
Innovative Platforms and Research
Amgen’s commitment to innovation is evident in its use of advanced platforms such as:
- BiTE® Technology: A pioneering immuno-oncology platform that engages T-cells to target cancer cells.
- Biosimilars: Amgen has a growing portfolio of biosimilars, offering cost-effective alternatives to existing biologics.
- Human Genetics: Through its subsidiary deCODE genetics, Amgen leverages genetic insights to identify disease pathways and develop precision medicines.
Strategic Collaborations and Acquisitions
Amgen actively collaborates with industry leaders like AstraZeneca and Kyowa Kirin to co-develop therapies such as TEZSPIRE and rocatinlimab. Its acquisition of Horizon Therapeutics has bolstered its portfolio in rare diseases, while its expertise in manufacturing ensures scalable production of biologics and biosimilars.
Market Position and Impact
Amgen is recognized for its strong financial performance and innovative pipeline. It is a component of the Dow Jones Industrial Average® and Nasdaq-100 Index®, reflecting its influence in the biopharmaceutical sector. The company’s global reach ensures access to life-saving therapies for millions of patients worldwide, while its robust R&D investments position it as a leader in addressing unmet medical needs.
Commitment to Sustainability and Ethics
Amgen is dedicated to environmental, social, and governance (ESG) initiatives, aiming to reduce its carbon footprint and enhance access to medicines. Its focus on ethical practices and patient-centric innovation underscores its role as a trusted leader in biotechnology.
Amgen and Kyowa Kirin have announced a global collaboration to jointly develop KHK4083, a potential first-in-class treatment for moderate-to-severe atopic dermatitis. Amgen will lead the development and commercialization worldwide, except in Japan, where Kyowa Kirin retains rights. The agreement includes a $400 million upfront payment from Amgen and additional milestone payments up to $850 million. KHK4083 has shown promising Phase 2 results, significantly improving symptoms in patients. The partnership builds on a long history of collaboration, leveraging Amgen's expertise and Kyowa Kirin's innovative technology.
Amgen (NASDAQ: AMGN) will present at the 2021 Jefferies Healthcare Conference on June 3, 2021, at 1:30 p.m. ET. Murdo Gordon, executive vice president of Global Commercial Operations, will lead the presentation. The conference call will be streamed live online, accessible to media, investors, and the public. Interested individuals can access the webcast on Amgen's website, where it will also be archived for 90 days.
Amgen specializes in innovative therapeutics and aims to meet high unmet medical needs, enhancing health outcomes globally.
Amgen has received FDA approval for LUMAKRAS™ (sotorasib) to treat adults with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have undergone at least one prior therapy. This accelerated approval is based on positive data showing a 36% overall response rate and a median duration of response of 10 months from the CodeBreaK 100 trial. The approval represents a significant advancement in targeted therapies for this mutation, which affects about 13% of non-squamous NSCLC patients in the U.S. Amgen is also providing companion diagnostics for effective biomarker testing.
Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 21, 2021, at 11:20 a.m. ET. Dr. David M. Reese, the executive vice president of Research and Development, will represent the company. The conference call will be streamed live, accessible to media, investors, and the public via Amgen's website. An archived version of the webcast will be available for at least 90 days post-event. Amgen is committed to discovering and delivering innovative therapies targeting high unmet medical needs, advancing human health since 1980.
Amgen will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 21, 2021, at 11:20 a.m. ET. The presentation will be led by David M. Reese, M.D., Executive Vice President of Research and Development. A live audio broadcast will be available for media, investors, and the public. The webcast can be accessed on Amgen's website and will be available for replay for 90 days. Amgen focuses on delivering innovative human therapeutics to address significant medical needs.
Amgen (NASDAQ: AMGN) announced the presentation of new oncology data at the 2021 ASCO Annual Meeting from June 4-8, 2021. Key highlights include the first-time presentation of overall survival data from the Phase 2 CodeBreaK 100 trial for LUMAKRAS™ (sotorasib) in non-small cell lung cancer (NSCLC). Additionally, updated results for bemarituzumab in advanced gastric cancer will be shared. Amgen’s webcast investor call is set for June 4, 2021, at 4:00 p.m. ET, where executives will discuss these pivotal findings.
Amgen and AstraZeneca reported significant results from the NAVIGATOR Phase 3 trial of tezepelumab, a potential treatment for severe asthma, showcasing superiority across primary and secondary endpoints versus placebo. Key findings include a 77% reduction in annualized asthma exacerbation rates and an 85% reduction in hospitalization rates for patients treated with tezepelumab. Results also indicated improvements in lung function and quality of life. Despite setbacks in the SOURCE Phase 3 trial, where the primary endpoint was not met, further analyses showed promising outcomes for patients on chronic oral corticosteroid therapy.
Amgen (NASDAQ:AMGN) announced the presentation of four cardiovascular research abstracts at the American College of Cardiology's 70th Annual Scientific Session & Expo (ACC.21), taking place May 15-17, 2021. Key highlights include final data from the Repatha® (evolocumab) trial for HIV patients with high cholesterol, confirming its safety and efficacy. The PROFICIO program, encompassing 50 trials and over 47,000 patients, supports the treatment's impact on cardiovascular disease. With over one million patients treated with Repatha globally, Amgen is committed to advancing cardiovascular treatment.
Amgen announced that AstraZeneca submitted a Biologics License Application (BLA) for tezepelumab to the FDA. This potential first-in-class treatment aims to address severe asthma, with clinical trials indicating a significant reduction in asthma exacerbations. The pivotal NAVIGATOR Phase 3 trial showed tezepelumab's ability to reduce exacerbation rates regardless of baseline eosinophil counts, making it unique among biologics. Tezepelumab targets thymic stromal lymphopoietin, key in asthma inflammation.
This submission is a step towards offering a transformative treatment for severe asthma patients.
Amgen will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference on May 11, 2021, at 11:00 a.m. ET. Key executives, including David M. Reese, M.D., Murdo Gordon, and Peter H. Griffith, will deliver presentations. The conference will be accessible via a live audio webcast for media, investors, and the public on Amgen's website. An archived version will be available for at least 90 days. Amgen focuses on developing innovative therapies for serious illnesses, leveraging human genetics since 1980.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
What does Amgen Inc. specialize in?
What are Amgen's key products?
How does Amgen leverage human genetics in its research?
What are Amgen's recent innovations?
What is Amgen's role in the biosimilar market?
